Burden of illness of hepatitis C from a managed care organization perspective

References

• Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296–305
   PubMedGoogle Scholar
• National Institute of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. http://consensus.nih.gov/cons/116/116cdc statement.htm [Accessed May 2003]
   Google Scholar
• Pessoa MG, Wright TL. Hepatitis C infection in transplantation. Clin Liver Dis 1997;1:663–90
   PubMedGoogle Scholar
• Alter HJ, Seef LB. Recovery, persistence, and sequalae in hepatitis C infection: a perspective on long-term outcomes. Sem Liver Dis 2000;20:17–35
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. Hepatology 1997;26:2S–10S
   Google Scholar
• Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infections. Clinical Ther 2002;24(9):1363–83
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. [Hepatitis Interventional Therapy Group]. New Engl J Med 1998;339:1485–92
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. [International Hepatitis Interventional Therapy Group]. New Engl J Med 1998;339:1493–9
   Google Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. [International Hepatitis Interventional Therapy Group]. Lancet 1998;352:1426–32
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65
   PubMed Web of Science ®Google Scholar
• Wong, JB. Cost-effectiveness of treatment for chronic hepatitis C. Am J Med 1999;107(6B):74S–78S
   Google Scholar
• Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 5 and 12 months of interferon-a therapy for chronic hepatitis C. Ann Int Med 1997;127:866–74
   PubMed Web of Science ®Google Scholar
• Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999;171:189–93
   Google Scholar
• Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepatitis 1998;5(5):313–21
   PubMed Web of Science ®Google Scholar
• Bennett WG, Pauker SG, Davis GL, Qong JB. Modeling therapeutic benefit in the midst of uncertainty. Therapy for hepatitis C. Dig Dis Sci 1996;41(12 Suppl):56S–62S
   Google Scholar
• Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318–24
   PubMed Web of Science ®Google Scholar
• Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. [International Hepatitis Interventional Therapy G]roup. Am J Gastroenterol 2000;95: 1524–30
   Google Scholar
• Koff RS, Fendrick M. Pharmacoeconomics of hepatitis C. P&T 2000;25:468–75
   Google Scholar
• Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000;33:651–8
   Google Scholar
• Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Int Med 2000;133:665–75
   PubMed Web of Science ®Google Scholar
• Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon-a-2b after interferon relapse in chronic hepatitis C. Am J Med 2000;108;355–73
   Google Scholar
• Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001;13:483–8
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Green J, Patel KK, et al. The cost-effectiveness of peginterferon alpha-2A (40KD) (Pegasys) plus ribavirin (Copegus) vs interferon alpha-2b plus ribavirin for chronic hepatitis C (CHC). Value in Health 2003;6(3):262–3 [Abstract]
   Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Pub Health 2000;90:1562–9
   PubMed Web of Science ®Google Scholar
• Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Cost of hepatitis C. Arch Int Med 2001;161:2231–7
   PubMed Web of Science ®Google Scholar
• Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag 2002;5(2):95–107
   Google Scholar
• Rosenberg DM, Cook SF, Lanza LL. Healthcare, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepatitis 2000;7:161–7
   Google Scholar
• Van Der Poel CL, Reesink HW, Lelie PN, et al. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet 1989;2:297–8
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med 1999;341:556–62
   PubMed Web of Science ®Google Scholar
• Delaporte E, Thiers V, Dazza MC, et al. High level of hepatitis C endemicity in Gabon, equatorial Africa. Trans R Soc Trop Med 1993;87:636–7
   PubMed Web of Science ®Google Scholar
• El-Ahmady O, Halim AB, Mansour O, Salman T. Incidence of hepatitis C virus in Egyptians. J Hepatol 1994;21:687
   Google Scholar
• Schaffer M, Phillips AL, Mansukani S. Costs of health care for hepatitis C-infected members in a managed care organization (MCO). Value in Health 2001;4:131 [abstract]
   Google Scholar
• Phillips AL, Schaffer M, Mansukani S. Ethnic disparity of combination ribavirin/interferon alfa-2b prescribed among hepatitis C-infected members in a managed care organization (MCO). Value in Health 2001;4:51–2 [abstract]
   Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1–5
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 2000;343:1666–72
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl J Med 2000;343:1673–80
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon a-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425–32
   PubMed Web of Science ®Google Scholar